News Fertility & pregnancy

Sensapex and IVF2.0 announce collaboration to enhance sperm injection for human IVF

By Published On: October 13, 2023
Sensapex and IVF2.0 announce collaboration to enhance sperm injection for human IVF
Sensapex (part of Acuvi AB), a leading developer of micromanipulators and automated workstations for cell manipulation, and IVF2.0, a pioneering provider of AI software for assisted reproductive technology (ART), have announced a strategic collaboration to further bring enhanced intracytoplasmic sperm injection (ICSI) solutions to the human IVF market.

Under the terms of the agreement, Sensapex will integrate its ultra-precise micromanipulators and microscope automation capabilities with IVF2.0’s innovative AI software that assists ICSI sperm selection.

By combining Sensapex’s cutting-edge hardware with IVF2.0’s data-driven software insights, the partners aim to develop the most advanced ICSI platform available.

“We are thrilled to partner with the outstanding team at IVF2.0 to merge our complementary areas of expertise in reproductive technology”, says Mikko Vähäsöyrinki, founder of Sensapex and VP of Acuvi Life Science Instrumentation business unit.

“This collaboration will allow us to deliver sophisticated new ICSI tools that improve consistency, precision and outcomes for IVF clinics and patients.”

Dr Andrew Drakeley, CEO of IVF2.0, says: “Sensapex is a perfect match for us as we enhance our AI software offerings.

“Their unique digitally integrated micromanipulation solutions will provide the specialised instrumentation to enhance our AI guidance smoothly and effectively in real-world IVF workflows.”

The companies expect the new integrated platform to be available for piloting by ART (Assisted Reproductive Technology) professionals within the next year.

About Sensapex

Sensapex provides cutting-edge robotic micromanipulators, microinjectors, and imaging systems for precision cell manipulation to labs and clinics worldwide. Learn more at www.sensapex.com.

About IVF2.0

IVF2.0 has the mission of improving IVF outcomes through Artificial Intelligence. Its innovative software platform uses AI and computer vision technology to enhance every step of the IVF process. Learn more at https://www.ivf20.ai/

Genea Biomedx and Future Fertility develop scientific partnership to streamline oocyte quality assessment and improve clinical outcomes in fertility labs
Scientists develop blood test for early-stage ovarian cancer